Shares of PureTech Health plc (NASDAQ:PRTC – Get Free Report) were down 6.3% during trading on Thursday . The stock traded as low as $17.04 and last traded at $17.55. Approximately 6,778 shares traded hands during mid-day trading, an increase of 273% from the average daily volume of 1,816 shares. The stock had previously closed at $18.73.
PureTech Health Price Performance
The company has a 50 day moving average of $20.84 and a 200 day moving average of $21.30.
About PureTech Health
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
Further Reading
- Five stocks we like better than PureTech Health
- Consumer Staples Stocks, Explained
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- What is a support level?
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
